

# Excessive prenatal supplementation of iodine and fetal goiter; report of management conservatively of fetal goiter: a case report

Birsen Konukcu<sup>1</sup> 

<sup>1</sup>Antalya City Hospital, Department of Perinatology, Antalya, Türkiye

## Abstract

**Objective:** Iodine is an essential mineral for the synthesis of thyroid hormones, so its deficiency can lead to serious problems. Therefore, routine iodine supplementation is recommended for pregnant women by World Health Organization. Fetal thyroid disorder is uncommon, and typically arises in the context of a managed maternal thyroid condition. Antithyroid therapy in mothers contributes to 10–15% of cases of congenital hypothyroidism in fetuses. The excessive iodine ingestion above daily intake limits during the pregnancy is a well-known mechanism among the known causes of fetal goiter. The occurrence of fetal goiter in babies of euthyroid mothers is quite rare. Fetal goiter, due to the maternal and fetal complications it causes, affects long-term morbidity and mortality. Among these complications are polyhydramnios, intrauterine growth restriction (IUGR), preterm birth, labor dystocia, hypoxia and brain damage resulting from airway obstruction caused by this mass.

**Case(s):** At 24 weeks pregnant, a 27-year-old primigravida was referred for a routine second trimester ultrasound evaluation despite not having a relevant family history or any personal thyroid or autoimmune illness, which showed cervical hyperextension and a high vascularized, bilobed, and symmetric mass in the anterior region of the fetal neck measuring 2.6 cm cranio-caudal × 1.5 cm transverse >95 SD, suggesting fetal goiter. No signs of polyhydramnios, and no other fetal anomalies were found. Overall, these findings stated fetal goiter.

**Conclusion:** The clinicians and healthcare providers should carefully review the medications and supplements used by patients and ensure they are being used at the correct dosage. Improper use of any medication can lead to teratogenic effects.

**Keywords:** Hypothyroidism, intrauterine treatment, euthyroid, fetal goiter, iodine supplementation

## Introduction

Adequate iodine nutrition is crucial for the synthesis of thyroid hormone. During pregnancy and lactation, there is an increased demand for dietary iodine.<sup>[1]</sup> During pregnancy, thyroid hormone production increases by 50%, leading to an elevation in daily iodine requirements.<sup>[2]</sup> This increase can be attributed to several factors: enhanced transportation of iodine across the placenta via active transport, heightened breakdown of thyroxine (T4) into the inactive form reverse triiodothyronine (T3), and a 30–50% increase in the renal excretion of iodide due to higher glomerular filtration rates. This surge typically begins in the latter half of the first trimester and persists throughout pregnancy.

Adequate iodine intake allows the thyroid gland to

adjust to the demands of pregnancy.<sup>[3]</sup>

The World Health Organization (WHO) have issued recommendations for iodine intake tailored to preconception, pregnancy, and postpartum periods. The WHO recommend 150 µg/day iodine intake for adults, which increases to 250 µg/day during pregnancy and lactation.<sup>[4,5]</sup>

Imbalance in iodine intake, whether excessive or deficient, can adversely affect thyroid function. High-dose iodine exposure triggers a temporary shutdown of thyroid hormone synthesis, termed the acute Wolff-Chaikoff effect.<sup>[6]</sup> Prolonged exposure to elevated iodine levels downregulates the sodium iodide symporter (NIS), facilitating the resumption of thyroid hormone synthesis,

**Correspondence:** Birsen Konukcu, Antalya City Hospital, Department of Perinatology, Antalya, Türkiye, **e-mail:** birsenkonukcu@hotmail.com,

**Received:** April 25, 2024, **Accepted:** June 21, 2024

**How to cite this article:** Konukcu B. Excessive prenatal supplementation of iodine and fetal goiter; report of management conservatively of fetal goiter: a case report. Perinatal Journal 2024;32(2):117-121 DOI: 10.59215/prn. 24.0322005

**ORCID ID:** B Konukcu 0000-0003-2235-4961




On the 24th week of gestation, the mother's urine iodine content was 972  $\mu\text{g/L}$  /24 h (normal range: 150–249  $\mu\text{g}$  /24 h).

When a detailed anamnesis was taken, it was learned that the patient had misunderstood the recommended dose of medication. It was learned that instead of two drops (250  $\mu\text{g}$ ), she used two droppers full of medicine (estimated 5000  $\mu\text{g}$ ) starting from the 4th week of pregnancy. Supplements were immediately discontinued and followed up at two week intervals

The patient was informed about the possibility of fetal goiter and hypothyroidism due to excessive iodine intake, along with all associated risks. Amniocentesis and cordocentesis were discussed, and it was explained that fetal TSH measurement would determine the treatment plan as needed, but she did not accept this and intra-amniotic therapy because of the potential risks of the procedures. She declined the invasive procedures and preferred to proceed with expectant management. Subsequent ultrasounds demonstrated resolution of the fetal goiter. During follow -up late onset IUGR was observed.

The patient decided to have her first child delivered by Cesarean. At 37 weeks gestation, she had this procedure, and the result was a 2340 g girl baby with an Apgar score of 8 at 1 minute and 9 at 5 minutes. The thyroid was not palpable at delivery. By the day of birth, postnatal thyroid scans showed a steady state of euthyroidism. The newborn's hearing screen confirmed both sides of the response to be normal. The baby was euthyroid, healthy, and reaching all developmental milestones at eight months of age.

**Fig 3.** Ultrasound demonstrating two hypoechogenic symmetric masses measuring 30 mm transvers length



**Fig 4.** Color Doppler of the fetal goiter, hypervascularization of the fetal thyroid gland

## Discussion

Fetal goiters are an unusual finding during pregnancy. When the mother does not have thyroid-stimulating antibodies and all other potential reasons of dysthyroidism are ruled out, it is necessary to look into other causes of fetal goiter. This case highlights the significance of looking for iatrogenic explanations for anomalies in fetuses. The natural iodine supplement our patient was taking was equal to 20 times the daily dosage of iodine prescribed during pregnancy. The hypothyroidism and fetal goiter were brought on by the high iodine dosage. Iodine passes through the placenta actively during pregnancy.<sup>1</sup> Iodine is concentrated in the thyroid gland and is essential for the synthesis of thyroid hormones. The recommended daily allowance for pregnant women is 250  $\mu\text{g}$  iodine daily.<sup>[4]</sup>

This case report sheds light on the consequences of maternal excessive iodine intake, which can result in conditions such as fetal goiter, as seen in our case. Additionally, this case presentation demonstrates the immaturity of the Wolff-Chaikoff effect in fetuses, indicating that they have not yet developed the ability to escape from it. The fetus is thought to be particularly susceptible to the suppressive effects of excessive iodine because it cannot avoid the Wolff-Chaikoff effect, a defensive mechanism that stops the creation of excess thyroid hormone in the event that plasma iodine levels abruptly rise.<sup>[6-8]</sup> Excessive iodine consumption in healthy individuals momentarily and abruptly impairs thyroid hormone secretion and thyroid biosynthesis. Following an extended period of exposure to high levels of iodine, organification and thyroid hormone biosynthesis proceed normally. The developing fetal and neonatal thyroid gland is unable to reduce intracellular iodine transport, in contrast to adults and children. Thus, the fetus continues to be hypothyroid.<sup>[7,8]</sup> Because fetuses have not yet developed the ability to escape from the Wolff-Chaikoff effect before 36 we-

eks, Formun Üstü excess iodine can result in persistent fetal hypothyroidism.<sup>[21,22]</sup> This effect resolves when the excessive iodine supplementation is removed.

In another case where fetal goiter developed following excessive iodine intake, it was observed that TSH levels returned to normal 5 weeks after the last iodine intake and 4 weeks after intra-amniotic levothyroxine treatment. To determine whether this condition was temporary or not, another fetal blood sample was taken after four weeks from the last intra-amniotic levothyroxine treatment, and it was shown that thyroid hormone synthesis had resumed.<sup>[23]</sup>

In our case, due to our patient not permitting cordocentesis, we don't know the levels of thyroid function tests. Delivery occurred 12 weeks after discontinuation of iodine supplementation, and thyroid functions were at normal levels, and fetal goiter was not observed. During pregnancy and childbirth, complications associated with fetal goiter may occur. Tracheal compression can result in postnatal asphyxia, intrathyroidal arteriovenous shunting can lead to high-output cardiac failure in the fetus and subsequent hydrops, and esophageal compression may diminish the fetus's capacity to ingest amniotic fluid, contributing to polyhydramnios, thereby increasing the likelihood of preterm delivery.<sup>[20]</sup> In addition, neck hyperextension from the goiter could result in malpresentation during delivery and delivery dystocia may occur.<sup>[24]</sup> In our case, three weeks after discontinuation of iodine, fetal goiter had resolved, and fetal neck hyperextension had improved on examination. Therefore, these complications were not observed in our case.

One of the obstetric complications seen in cases of fetal goiter is intrauterine growth retardation (IUGR). In a retrospective study conducted in 2022, it was noted that 11 of 31 congenital goiter cases where antenatal diagnosis could not be made, IUGR developed.

In our case as well, despite the cessation of iodine and regression of the goiter, IUGR developed. Our patient resembles cases recently described in a case report by Overcash et al. and another case report by Hardley M et al.<sup>[23,25]</sup> In both cases, the mothers were also exceeding the recommended iodine dosage during pregnancy, leading to fetal goiter. In the case reported by Overcash, the patient did not receive intra-amniotic levothyroxine injections. Subsequently, the infant was diagnosed with bilateral hearing loss, a recognized complication of fetal hypothyroidism.<sup>[25]</sup> Hearing screening in the other case which one treated with intra-amniotic levothyroxine injections revealed a normal response bilaterally.<sup>[23]</sup> In our case, intrauterine levothyroxine treatment could not be administered because the patient did not consent to any

invasive procedures. Postnatal follow-up examinations revealed normal bilateral hearing tests in both ears.

Additional research is required to ascertain whether intra-amniotic therapy for hypothyroid fetuses substantially reduces the incidence of postnatal sensorineural hearing loss.

## Conclusion

In conclusion, our case highlights the importance of timely diagnosis and management of fetal goiter to prevent potential obstetric complications. While antenatal detection and treatment options were limited in our case due to patient preferences, postnatal assessments showed positive outcomes, including the resolution of fetal goiter and normal bilateral hearing tests.

Another point we want to emphasize with this study is that clinicians and healthcare providers should carefully review the medications and supplements used by patients and ensure they are being used at the correct dosage. Improper use of any medication can lead to teratogenic effects.

## References

- Rodriguez-Diaz, E., & Pearce, E. N. (2020). Iodine status and supplementation before, during, and after pregnancy. In *Best Practice and Research: Clinical Endocrinology and Metabolism* (Vol. 34, Issue 4). Bailliere Tindall Ltd. [[PubMed](#)][[CrossRef](#)]
- Alexander EK, Pearce EN, Brent GA, Brown RS et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid* 2017; 27: 315-389. (n.d.). [[PubMed](#)][[CrossRef](#)]
- Leung AM, Pearce EN & Braverman LE. Iodine nutrition in pregnancy and lactation. *Endocrinology and Metabolism Clinics of North America* 2011; 40: 765-777. . (n.d.). [[PubMed](#)][[CrossRef](#)]
- WHO Secretariat, Andersson M, de Benoist B, Delange F & Zupan J. Prevention and control of iodine deficiency in pregnant and lactating women and in children less than 2-years-old: conclusions and recommendations of the Technical Consultation. *Public Health Nutrition* 2007; 10: 1606-1611. (n.d.). [[PubMed](#)][[CrossRef](#)]
- Institute of Medicine: Dietary Reference Intakes for Vitamin A, vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. Washington DC: National Academy Press; 2001. (n.d.).
- Leung AM & Braverman LE. Consequences of excess iodine. *Nature Reviews Endocrinology* 2014; 10: 136-142. (n.d.). [[PubMed](#)][[CrossRef](#)]
- Wolff J, Chaikoff IL, et al. The temporary nature of the inhibitory action of excess iodine on organic iodine synthesis in the normal thyroid. *Endocrinology*. 1949;45(5):504-513, illust. (n.d.). [[PubMed](#)][[CrossRef](#)]



8. Wolff J, Chaikoff IL. Plasma inorganic iodide as a homeostatic regulator of thyroid function. *J Biol Chem.* 1948;174(2):555–564. (n.d.). [[PubMed](#)][[CrossRef](#)]
9. Theodoropoulos T, Braverman LE & Vagenakis AG. Iodide-induced hypothyroidism: a potential hazard during perinatal life. *Science* 1979; 205: 502–503. (n.d.). [[PubMed](#)][[CrossRef](#)]
10. Shi X, Han C, Li C, Mao J et al. Optimal and safe upper limits of iodine intake for early pregnancy in iodine-sufficient regions: a cross-sectional study of 7190 pregnant women in China. *Journal of Clinical Endocrinology and Metabolism* 2015;100:1630–8. (n.d.). [[PubMed](#)][[CrossRef](#)]
11. Delay F, Dochez V, Biquard F, Cheve MT, Gillard P, Arthuis CJ, Winer N. Management of fetal goiters: 6-year retrospective observational study in three prenatal diagnosis and treatment centers of the Pays De Loire Perinatal Network. *Journal of Maternal-Fetal and Neonatal Medicine*, 2020 33(15), 2561–2569. [[PubMed](#)][[CrossRef](#)]
12. Munoz JL. Fetal thyroid disorders: Pathophysiology, diagnosis and therapeutic approaches. *Journal of Gynecology Obstetrics and Human Reproduction.* 2019;48(4), 231–233 [[PubMed](#)][[CrossRef](#)]
13. Ferianec V, Papcun P, Grochal F, Schenková K, Bártoová M. Prenatal diagnosis and successful intrauterine treatment of severe congenital hypothyroidism associated with fetal goiter. *Journal of Obstetrics and Gynaecology Research.* 2017;43(1), 232–237. [[PubMed](#)][[CrossRef](#)]
14. Stewart CJM, Constantatos S, Joolay Y, Muller L. In utero treatment of fetal goitrous hypothyroidism in a euthyroid mother: A case report. *Journal of Clinical Ultrasound*, 2012;40(9), 603–606. [[PubMed](#)][[CrossRef](#)]
15. Khamisi S, Lindgren P, Karlsson FA. A Rare Case of Dyshormonogenetic Fetal Goiter Responding to Intra-Amniotic Thyroxine Injections. *European Thyroid Journal.* 2014;3(1), 51–56. [[PubMed](#)][[CrossRef](#)]
16. Ogamo M, Sugiyama T, Maeda Y, Kusaka H, Utsunomiya H, Tsubouchi M, Uchida K, Sasaki N, Mitani Y, Komada Y, Toyoda N. The ex utero intrapartum treatment (EXIT) procedure in giant fetal neck masses: A case report and review of the literature. In *Fetal Diagnosis and Therapy* 2005;20(3),214–218. [[PubMed](#)][[CrossRef](#)]
17. Ribault V, Castanet M, Bertrand AM, Guibourdenche J, Vuillard E, Luton D, Polak M, Thibault H, Idres N, Bony-Triffunovic H, Perrotin F, Cabrol S, Houang M, Naud-Saudreau C, Crosnier H. Experience with intraamniotic thyroxine treatment in nonimmune fetal goitrous hypothyroidism in 12 cases. *Journal of Clinical Endocrinology and Metabolism*, 2009;94(10), 3731–3739. [[PubMed](#)][[CrossRef](#)]
18. Rosenfeld H, Ornoy A, Shechtman S, Diav-Citrin O. Pregnancy outcome, thyroid dysfunction and fetal goitre after in utero exposure to propylthiouracil: A controlled cohort study. *British Journal of Clinical Pharmacology*, 2009; 68(4), 609–617. [[PubMed](#)][[CrossRef](#)]
19. Polak M, Le Gac I, Vuillard E, Guibourdenche J, Leger J, Toubert ME, Madec AM, Oury JF, Czernicchow P, Luton D. Fetal and neonatal thyroid function in relation to maternal Graves' disease. In *Best Practice and Research: Clinical Endocrinology and Metabolism* 2004;18(2): 289–302. Bailliere Tindall Ltd. [[PubMed](#)][[CrossRef](#)]
20. Mastrolia SA, Mandola A, Mazor M, HersHKovitz R, Mesner O, Beer-Weisel R, Besser L, Shelef I, Loewenthal N, Golan A, Gruzman I, Erez O. Antenatal diagnosis and treatment of hypothyroid fetal goiter in an euthyroid mother: A case report and review of literature. In *Journal of Maternal-Fetal and Neonatal Medicine* 2015;28(18):2214–2220. Taylor and Francis Ltd. [[PubMed](#)][[CrossRef](#)]
21. De Vasconcellos Thomas J, Collett-Solberg PF. Perinatal goiter with increased iodine uptake and hypothyroidism due to excess maternal iodine ingestion. *Hormone Research*, 2009;72(6), 344–347. [[PubMed](#)][[CrossRef](#)]
22. Castro P, Werner H, Marinho PRS, Matos AP, Pires P, Araujo Júnior E. Excessive Prenatal Supplementation of Iodine and Fetal Goiter: Report of Two Cases Using Three-dimensional Ultrasound and Magnetic Resonance Imaging. *Revista Brasileira de Ginecologia e Obstetricia*, 2021;43(4), 317–322 [[PubMed](#)][[CrossRef](#)]
23. Hardley MT, Chon AH, Mestman J, Nguyen CT, Geffner ME, Chmait RH. Iodine-Induced Fetal Hypothyroidism: Diagnosis and Treatment with Intra-Amniotic Levothyroxine. *Hormone Research in Paediatrics*, 2019; 90(6), 419–423. [[PubMed](#)][[CrossRef](#)]
24. Blumenfeld YJ, Davis A, Milan K, Chueh J, Hudgins L, Barth RA, Hintz SR. Conservatively managed fetal goiter: An alternative to in utero therapy. *Fetal Diagnosis and Therapy*, 2013;34(3), 184–187. [[PubMed](#)][[CrossRef](#)]
25. Overcash RT, Marc-Aurele KL, Hull AD, Ramos GA. Maternal iodine exposure: A case of fetal goiter and neonatal hearing loss. *Pediatrics*. 2016. [[PubMed](#)][[CrossRef](#)]